• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Athenex Inc. (Amendment)

    2/14/22 3:50:00 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNX alert in real time by email
    SC 13G/A 1 d275600dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Athenex, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    04685N103

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 04685N103

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Advisors LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      13,532,467

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      13,532,467

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      13,532,467

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      12.4%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA


    CUSIP No. 04685N103

     

      1    

      NAMES OF REPORTING PERSONS

     

      Joseph Edelman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      13,532,467

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      13,532,467

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      13,532,467

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      12.4%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    CUSIP No. 04685N103

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Life Sciences Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      13,532,467

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      13,532,467

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      13,532,467

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      12.4%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO


    Item 1(a).

    Name of Issuer:

    Athenex, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    1001 Main Street, Suite 600, Buffalo, NY 14203

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common stock, $0.001 par value per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    04685N103

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based 109,319,039 outstanding shares of Common Stock as reported in the Issuer’s Form 10-Q filed on November 4, 2021.


    The Master Fund directly holds 13,532,467 shares of Common Stock. Perceptive Advisors serves as the investment manager to the funds and may be deemed to beneficially own the securities directly held by the funds. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the funds.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

    PERCEPTIVE ADVISORS LLC

     

    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

     

    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member
    Get the next $ATNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNX

    DatePrice TargetRatingAnalyst
    10/12/2021$8.00 → $5.00Outperform
    RBC Capital
    8/6/2021$9.00 → $8.00Outperform
    RBC Capital
    8/6/2021$5.00 → $4.00Market Perform
    SVB Leerink
    More analyst ratings

    $ATNX
    Financials

    Live finance-specific insights

    See more
    • Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

      Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

      3/20/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

      BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: 1-844-826-3033 International: 1-412-317-5185 Pass

      10/24/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Provides Second Quarter 2022 Financial Results and Business Update

      Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 millionCash used in operating activities for 1H 2022 was reduced 42% over the prior yearPresented promising early Phase 1 clinical trial data for CD19 and GD2 CAR-NKT cell products at ASTCT/CIBMTR Tandem Meetings and ASGCT annual meeting in 2Q 2022, respectivelyMaintains full-year 2022 product revenue guidance range of 20-25% growth year-over-year Management to host conference call and webcast today at 8:00 a.m. EDT BUFFALO, N.Y.

      7/28/22 7:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

      To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX) ("Athenex" or the "Company"), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company's assets across its primary businesses: Athenex Pharmaceu

      5/14/23 11:15:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

      Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

      3/20/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Announces a Reverse Stock Split

      BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on November 22, 2022, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's common stock, at

      2/14/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

      BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy. "We are delighted to welcome Dr. Cohen to Athenex during this transformative period, as we strategically pivot to focus on advancing first-in-class

      6/8/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Announces Appointment of Chief Financial Officer

      BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity, investment banking, and Big4 Advisory, with over 20 years of corporate finance experience. "The Board of Directors joins me in welcoming Joe to his new position as CFO," said Johnson Lau, Chief

      2/22/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Lau Johnson Yiu Nam

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:36:36 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kwan Rudolf

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:33:18 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cook Timothy Devere

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:29:48 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FAMOTIDINE issued to ATHENEX INC

      Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

      1/12/22 4:41:30 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KLISYRI

      Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

      12/20/20 4:30:55 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Athenex Inc. (Amendment)

      SC 13D/A - Athenex, Inc. (0001300699) (Subject)

      2/14/23 4:10:55 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Athenex Inc.

      SC 13D - Athenex, Inc. (0001300699) (Subject)

      2/2/23 5:01:53 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Athenex Inc. (Amendment)

      SC 13G/A - Athenex, Inc. (0001300699) (Subject)

      2/14/22 3:50:00 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on Athenex with a new price target

      RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $5.00 from $8.00 previously

      10/12/21 6:58:34 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Athenex with a new price target

      RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $8.00 from $9.00 previously

      8/6/21 9:52:27 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Athenex with a new price target

      SVB Leerink reiterated coverage of Athenex with a rating of Market Perform and set a new price target of $4.00 from $5.00 previously

      8/6/21 5:46:15 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    SEC Filings

    See more
    • Athenex Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      10/2/23 7:42:29 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Inc. filed SEC Form 8-K: Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      8/17/23 4:06:01 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      7/18/23 9:03:58 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care